osimertinib sold brand name medication used treat nonsmallcell lung carcinomas specific thirdgeneration epidermal growth factor receptor tyrosine kinase inhibitor common side effects include diarrhea rash musculoskeletal pain dry skin skin inflammation around nails sore mouth fatigue osimertinib approved medical use united states november european union february osimertinib used treat locally advanced metastatic nonsmallcell lung cancer nsclc cancer cells positive mutation gene coding egfr activating egfr mutation may de novo acquired following firstline treatment egfr tyrosine kinase inhibitors gefitinib erlotinib us egfr exon deletions exon mutations status patient prior treatment osimertinib must detected companion diagnostic food drug administration fda approved multiple tests including foundationone cdx europe elsewhere activating egfr mutations mutations may determined validated people treated osimertinib resistance usually develops within approximately resistance mediated exon mutation accounts majority resistance resulted multiple attempts nonatp competitive allosteric inhibitors try offset acquired resistance targeting regions rtk kinase cause fetal harm used women pregnant women take avoid becoming caution taken people history interstitial lung disease ild excluded clinical trials since drug cause severe ild pneumonitis caution also taken people predisposition long qt syndrome drug provoke common greater clinical trial subjects adverse effects include diarrhea stomatitis rashes dry itchy skin infections finger toenails abut skin low platelet counts low leukocyte counts low neutrophil common clinical trial subjects adverse effects include interstitial lung osimertinib metabolized substances strongly inhibit either enzyme like macrolide antibiotics antifungals antivirals may increase exposure osimertinib substances like rifampicin activate either enzyme may decrease effectiveness osimertinib preferentially binds irreversibly mutated epidermal growth factor receptor proteins particularly common mutations lung cancer mutation exon exhibits linear pharmacokinetics median time cmax hours range hours estimated mean halflife hours oral clearance clf elimination feces osimertinib provided mesylate chemical formula molecular weight gmol chemical name mesylate drug discovery program led osimertinib started yielded drug process structuredriven aimed find third generation egfr inhibitor would selectively target form egfr osimertinib designated breakthrough therapy april based phase trial drug provisionally approved fda accelerated approval program priority review voucher november february ema provisionally approved osimertinib accelerated first approval launch united states astrazeneca priced drug per several clinical trials httpsenwikipediaorgwikiosimertinib